How Tirzepatide Fights Atherosclerosis: Mechanistic Review of GLP-1/GIP Vascular Protection | Research

The takeaway

Review examines the mechanistic role of tirzepatide in atherosclerosis, covering anti-inflammatory, endothelial protective, lipid-modifying, and plaque-stabilizing mechanisms of GLP-1/GIP dual agonism.

Multi-mechanism anti-plaque
Tirzepatide fights atherosclerosis through at least 5 mechanisms via dual GLP-1/GIP receptor activation in blood vessels

What the researchers found

Tirzepatide combats atherosclerosis through anti-inflammatory, endothelial protective, lipid-modifying, and plaque-stabilizing mechanisms via dual GLP-1/GIP receptor activation.

Why it matters

Atherosclerosis drives most cardiovascular deaths. Understanding how tirzepatide — beyond weight loss — directly fights plaque formation could position it as an anti-atherosclerotic drug.

The numbers in context

Review article synthesizing evidence across multiple studies on tirzepatide's anti-atherosclerotic mechanisms.

How the study worked

Mechanistic review of tirzepatide anti-atherosclerotic properties, covering preclinical and clinical evidence for each proposed mechanism.

Who was studied

Review covering various populations from preclinical to clinical studies

What this study cannot tell us

Most mechanistic evidence is preclinical. Dedicated atherosclerosis outcome trials for tirzepatide are not yet complete. The relative contributions of GLP-1 vs GIP vascular effects are unclear.

How to read the evidence

Moderate evidence: mechanistic review with strong preclinical rationale and emerging clinical support.

When this study was published

Published in 2025. Timely ahead of tirzepatide cardiovascular outcome trial results.

The bigger picture

Tirzepatide's dual agonism may provide vascular protection that single GLP-1 drugs cannot match. The GIP receptor — traditionally associated with fat storage — appears to have independent anti-atherosclerotic properties, adding a second line of vascular defense.

Questions still open

Does tirzepatide reduce atherosclerosis more than semaglutide due to added GIP effects?
Will the SURPASS-CVOT cardiovascular outcome trial confirm anti-atherosclerotic benefits?
Could tirzepatide be used specifically as an anti-atherosclerotic drug?

Common questions

Does tirzepatide protect blood vessels?

Multiple mechanisms suggest yes — tirzepatide reduces vascular inflammation, improves blood vessel lining health, modifies lipids, and may stabilize existing plaques. Both GLP-1 and GIP receptor activation contribute to these vascular effects.

Is tirzepatide better than semaglutide for atherosclerosis?

The added GIP receptor activation may provide additional anti-atherosclerotic effects that semaglutide (GLP-1 only) does not. However, this comparison awaits the SURPASS-CVOT cardiovascular outcome trial results.

Read the original research

The mechanistic role of tirzepatide in atherosclerosis: A review.

International journal of biological macromolecules, 329(Pt 1), 147734

View on PubMed ↗Publisher’s paper ↗

Citation

Al-Kuraishy, Hayder M; Sulaiman, Ghassan M; Mohammed, Hamdoon A; Saad, Hebatallah M; Waheed, Huda J; Jabir, Majid S; Al-Gareeb, Ali I; Albuhadily, Ali K. (2025). The mechanistic role of tirzepatide in atherosclerosis: A review.. International journal of biological macromolecules, 329(Pt 1), 147734. https://doi.org/10.1016/j.ijbiomac.2025.147734